A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

BACKGROUND: To evaluate the immunomodulating and clinical effects of nilotinib, a tyrosine kinase inhibitor, in a proof-of-concept study in spondyloarthritis (SpA) assessing the mast cell as potential novel therapeutic target in this disease. METHODS: Twenty eight patients with active peripheral (pS...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Transl Med
Autors principals: Paramarta, Jacqueline E., Turina, Maureen C., Noordenbos, Troy, Heijda, Tanja F., Blijdorp, Iris C., Yeremenko, Nataliya, Baeten, Dominique
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081668/
https://ncbi.nlm.nih.gov/pubmed/27784336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-1050-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars